Phase I study of eptifibatide in patients with sickle cell anaemia

British Journal of Haematology

Volumn 139, Issue 4, 2007, Pages 612-620

  Lee, Sheritha P ^a   Ataga, Kenneth I ^a   Zayed, Mohamed ^a   Manganello, Jeanne M ^b,c   Orringer, Eugene P ^a   Phillips, David R ^b,d   Parise, Leslie V ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

^c PFIZER INC   (United States)

^d Portola Pharmaceuticals Inc   (United States)

Author keywords

CD40 ligand; Eptifibatide; Inflammation; Platelet; Sickle cell anaemia

Indexed keywords

BETA THROMBOGLOBULIN; CD40 LIGAND; EPTIFIBATIDE; GELATINASE A; GELATINASE B; HYDROXYUREA; LEPTIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MYOGLOBIN; PADGEM PROTEIN; THROMBOCYTE FACTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BETA THROMBOGLOBULIN BLOOD LEVEL; BLEEDING; BLOOD CLOTTING; BLOOD LEVEL; CASE REPORT; CLINICAL TRIAL; CONTINUOUS INFUSION; CORRELATION ANALYSIS; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEMATOLOGICAL PARAMETERS; HUMAN; LEUKOCYTE AGGREGATION; MALE; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PLATELET FACTOR 4 BLOOD LEVEL; PRIORITY JOURNAL; SICKLE CELL ANEMIA; SIDE EFFECT; THROMBOCYTE AGGREGATION;

ADULT; ANEMIA, SICKLE CELL; ANTIGENS, CD40; BLOOD PLATELETS; CYTOKINES; HUMANS; LEUKOCYTES; MALE; MATRIX METALLOPROTEINASES; PEPTIDES; PLATELET AGGREGATION INHIBITORS;

EID: 35748939673     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2007.06787.x     Document Type: Article

References (48)

1. Aggarwal, A., Schneider, D.J., Terrien, E.F., Terrien, Jr., C.M., Sobel, B.E. Dauerman, H.L. (2003) Comparison of effects of abciximab versus eptifibatide on C-reactive protein, interleukin-6, and interleukin-1 receptor antagonist after coronary arterial stenting. American Journal of Cardiology, 91, 1346 1349.
2. Ataga, K.I. Orringer, E.P. (2003) Hypercoagulability in sickle cell disease: a curious paradox. American Journal of Medicine, 115, 721 728.
3. Azar, R.R., Kassab, R., Zoghbi, A., Aboujaoude, S., El Osta, H., Ghorra, P., Germanos, M. Salame, E. (2006) Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease. American Heart Journal, 151, 521.
4. Belcher, J.D., Marker, P.H., Weber, J.P., Hebbel, R.P. Vercellotti, G.M. (2000) Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion. Blood, 96, 2451 2459.
5. Berney, S.I., Ridler, C.D., Stephens, A.D., Thomas, A.E. Kovacs, I.B. (1992) Enhanced platelet reactivity and hypercoagulability in the steady state of sickle cell anaemia. American Journal of Hematology, 40, 290 294.
6. Brittain, J.E., Mlinar, K.J., Anderson, C.S., Orringer, E.P. Parise, L.V. (2001) Activation of sickle red blood cell adhesion via integrin-associated protein/CD47-induced signal transduction. Journal of Clinical Investigation, 107, 1555 1562.
7. Byzova, T.V. Plow, E.F. (1997) Networking in the hemostatic system. Integrin alphaIIbbeta3 binds prothrombin and influences its activation. Journal of Biological Chemistry, 272, 27183 27188.
8. Curran, M.P. Keating, G.M. (2005) Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention. Drugs, 65, 2009 2035.
9. Dale, G.L., Friese, P., Batar, P., Hamilton, S.F., Reed, G.L., Jackson, K.W., Clemetson, K.J. Alberio, L. (2002) Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface. Nature, 415, 175 179.
10. Frishman, W.H. Grewall, P. (2000) Serotonin and the heart. Annals of Medicine, 32, 195 209.
11. Furman, M.I., Krueger, L.A., Linden, M.D., Barnard, M.R., Frelinger, III., A.L. Michelson, A.D. (2004) Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization. Journal of the American College of Cardiology, 43, 2319 2325.
12. Furman, M.I., Krueger, L.A., Linden, M.D., Fox, M.L., Ball, S.P., Barnard, M.R., Frelinger, III., A.L. Michelson, A.D. (2005) GPIIb-IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Journal of Thrombosis and Haemostasis, 3, 312 320.
13. Hebbel, R.P., Osarogiagbon, R. Kaul, D. (2004) The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirculation, 11, 129 151.
14. Heeschen, C., Dimmeler, S., Hamm, C.W., van den Brand, M.J., Boersma, E., Zeiher, A.M. Simoons, M.L. (2003) Soluble CD40 ligand in acute coronary syndromes. New England Journal of Medicine, 348, 1104 1111.
15. Heitzer, T., Ollmann, I., Koke, K., Meinertz, T. Munzel, T. (2003) Platelet glycoprotein IIb/IIIa receptor blockade improves vascular nitric oxide bioavailability in patients with coronary artery disease. Circulation, 108, 536 541.
16. Henn, V., Slupsky, J.R., Grafe, M., Anagnostopoulos, I., Forster, R., Muller-Berghaus, G. Kroczek, R.A. (1998) CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature, 391, 591 594.
17. Keating, F.K., Dauerman, H.L., Whitaker, D.A., Sobel, B.E. Schneider, D.J. (2006) Increased expression of platelet P-selectin and formation of platelet-leukocyte aggregates in blood from patients treated with unfractionated heparin plus eptifibatide compared with bivalirudin. Thrombosis Research, 118, 361 369.
18. Key, N.S., Slungaard, A., Dandelet, L., Nelson, S.C., Moertel, C., Styles, L.A., Kuypers, F.A. Bach, R.R. (1998) Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood, 91, 4216 4223.
19. Kuypers, F.A., Lewis, R.A., Hua, M., Schott, M.A., Discher, D., Ernst, J.D. Lubin, B.H. (1996) Detection of altered membrane phospholipid asymmetry in subpopulations of human red blood cells using fluorescently labeled annexin V. Blood, 87, 1179 1187.
20. Lee, Y., Lee, W.H., Lee, S.C., Ahn, K.J., Choi, Y.H., Park, S.W., Seo, J.D. Park, J.E. (1999) CD40L activation in circulating platelets in patients with acute coronary syndrome. Cardiology, 92, 11 16.
21. Lee, S.P., Ataga, K.I., Orringer, E.P., Phillips, D.R. Parise, L.V. (2006) Biologically active CD40 ligand is elevated in sickle cell anemia. Potential role for platelet-mediated inflammation. Arteriosclerosis, Thrombosis, and Vascular Biology, 26, 1626 1631.
22. Marcondes, S., Lafay, M., Brohard-Bohn, B., de Nucci, G. Rendu, F. (2000) Platelets induce human umbilical vein endothelial cell proliferation through P-selectin. Life Sciences, 66, 1817 1826.
23. Massberg, S., Mueller, I., Besta, F., Thomas, P. Gawaz, M. (2003) Effects of 2 different antiplatelet regimens with abciximab or tirofiban on platelet function in patients undergoing coronary stenting. American Heart Journal, 146, E19.
24. Matsui, N.M., Borsig, L., Rosen, S.D., Yaghmai, M., Varki, A. Embury, S.H. (2001) P-selectin mediates the adhesion of sickle erythrocytes to the endothelium. Blood, 98, 1955 1962.
25. Michelson, A.D. (2000) Flow cytometric analysis of platelets. Vox Sanguinis, 78 (Suppl. 2 137 142.
26. Moser, M., Bertram, U., Peter, K., Bode, C. Ruef, J. (2003) Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates. Journal of Cardiovascular Pharmacology, 41, 586 592.
27. Nannizzi-Alaimo, L., Alves, V.L. Phillips, D.R. (2003) Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation, 107, 1123 1128.
28. Nylaende, M., Kroese, A., Stranden, E., Morken, B., Sandbaek, G., Lindahl, A.K., Arnesen, H. Seljeflot, I. (2006) Markers of vascular inflammation are associated with the extent of atherosclerosis assessed as angiographic score and treadmill walking distances in patients with peripheral arterial occlusive disease. Vascular Medicine, 11, 21 28.
29. O'Shea, J.C., Buller, C.E., Cantor, W.J., Chandler, A.B., Cohen, E.A., Cohen, D.J., Gilchrist, I.C., Kleiman, N.S., Labinaz, M., Madan, M., Hafley, G.E., Califf, R.M., Kitt, M.M., Strony, J. Tcheng, J.E. (2002) Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. The journal of American Medical Association, 287, 618 621.
30. Oliver, K.G., Kettman, J.R. Fulton, R.J. (1998) Multiplexed analysis of human cytokines by use of the FlowMetrix system. Clinical Chemistry, 44, 2057 2060.
31. Palabrica, T., Lobb, R., Furie, B.C., Aronovitz, M., Benjamin, C., Hsu, Y.M., Sajer, S.A. Furie, B. (1992) Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature, 359, 848 851.
32. Papadimitriou, C.A., Travlou, A., Kalos, A., Douratsos, D. Lali, P. (1993) Study of platelet function in patients with sickle cell anemia during steady state and vaso-occlusive crisis. Acta Haematologica, 89, 180 183.
33. Phillips, D.R. Agin, P.P. (1977) Platelet membrane defects in Glanzmann's thrombasthenia. Evidence for decreased amounts of two major glycoproteins. Journal of Clinical Investigation, 60, 535 545.
34. Platt, O.S. (2000) Sickle cell anemia as an inflammatory disease. Journal of Clinical Investigation, 106, 337 338.
35. Prasad, K.S., Andre, P., Yan, Y. Phillips, D.R. (2003) The platelet CD40L/GP IIb-IIIa axis in atherothrombotic disease. Current Opinion in Hematology, 10, 356 361.
36. Puma, J.A., Banko, L.T., Pieper, K.S., Sacchi, T.J., O'Shea, J.C., Dery, J.P. Tcheng, J.E. (2006) Clinical characteristics predict benefits from eptifibatide therapy during coronary stenting: insights from the enhanced suppression of the platelet IIb/IIIa receptor with integrilin therapy (ESPRIT) trial. Journal of the American College of Cardiology, 47, 715 718.
37. Savage, B., Saldivar, E. Ruggeri, Z.M. (1996) Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell, 84, 289 297.
38. Scholz, T., Zhao, L., Temmler, U., Bath, P., Heptinstall, S. Losche, W. (2002) The GPIIb/IIIa antagonist eptifibatide markedly potentiates platelet-leukocyte interaction and tissue factor expression following platelet activation in whole blood in vitro. Platelets, 13, 401 406.
39. Schonbeck, U. Libby, P. (2001) The CD40/CD154 receptor/ligand dyad. Cellular Molecular Life Science, 58, 4 43.
40. Schonbeck, U., Mach, F. Libby, P. (2000) CD154 (CD40 ligand). International Journal of Biochemistry and Cell Biology, 32, 687 693.
41. Schonbeck, U., Varo, N., Libby, P., Buring, J. Ridker, P.M. (2001) Soluble CD40L and cardiovascular risk in women. Circulation, 104, 2266 2268.
42. Setty, B.N., Kulkarni, S., Rao, A.K. Stuart, M.J. (2000) Fetal hemoglobin in sickle cell disease: relationship to erythrocyte phosphatidylserine exposure and coagulation activation. Blood, 96, 1119 1124.
43. Shet, A.S., Aras, O., Gupta, K., Hass, M.J., Rausch, D.J., Saba, N., Koopmeiners, L., Key, N.S. Hebbel, R.P. (2003) Sickle blood contains tissue factor positive microparticles derived from endothelial cells and monocytes. Blood, 102, 2678 2683.
44. Solovey, A., Kollander, R., Shet, A., Milbauer, L.C., Choong, S., Panoskaltsis-Mortari, A., Blazar, B.R., Kelm, Jr., R.J. Hebbel, R.P. (2004) Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatin. Blood, 104, 840 846.
45. Tcheng, J.E. (1997) Impact of eptifibatide on early ischemic events in acute ischemic coronary syndromes: a review of the IMPACT II trial. Integrilin to minimize platelet aggregation and coronary thrombosis. American Journal of Cardiology, 80, 21B 28B.
46. Tcheng, J.E., Harrington, R.A., Kottke-Marchant, K., Kleiman, N.S., Ellis, S.G., Kereiakes, D.J., Mick, M.J., Navetta, F.I., Smith, J.E. Worley, S.J. (1995) Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators. Circulation, 91, 2151 2157.
47. Welt, F.G., Rogers, S.D., Zhang, X., Ehlers, R., Chen, Z., Nannizzi-Alaimo, L., Phillips, D.R. Simon, D.I. (2004) GP IIb/IIIa inhibition with eptifibatide lowers levels of soluble CD40L and RANTES after percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 61, 185 189.
48. Yip, H.K., Chang, L.T., Sun, C.K., Yang, C.H., Hung, W.C., Cheng, C.I., Chua, S., Yeh, K.H., Wu, C.J. Fu, M. (2006) Impact of clopidogrel on suppression of circulating levels of soluble CD40 ligand in patients with unstable angina undergoing coronary stenting. American Journal of Cardiology, 97, 192 194.